Phase III Study of Docetaxel Vs Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Vinorelbine is currently the standard treatment for elderly patients with advanced non-small
cell lung cancer (NSCLC). Docetaxel has also shown promising results against elderly patients
in phase II studies. We conducted a randomized phase III trial to evaluate whether docetaxel
provided better overall survival than vinorelbine in elderly patients with advanced NSCLC.